PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD.
about
Cholinergic imaging in dementia spectrum disordersPET Imaging of the Human Nicotinic Cholinergic Pathway in AtherosclerosisDifferent cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.Update on the pharmacological treatment of Alzheimer's diseaseUnveiling molecular events in the brain by noninvasive imaging.Brain imaging of nicotinic receptors in Alzheimer's disease.Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development.PET radiopharmaceuticals for probing enzymes in the brainA review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.Functional imaging of cognitive impairment in Parkinson's disease.PET probes for imaging brain acetylcholinesterase.Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status.The role of positron emission tomography imaging in understanding Alzheimer's disease.Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease.Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action.Alterations in Phase-Related Prefrontal Activation During Cognitive Tasks and Nicotinic α4β2 Receptor Availability in Alzheimer's Disease.Function of Plectranthus barbatus herbal tea as neuronal acetylcholinesterase inhibitor.The Place of PET to Assess New Therapeutic Effectiveness in Neurodegenerative Diseases.
P2860
Q26764933-133D406B-8968-42FD-A412-1C1A16C7E2C4Q26800058-1F4A5DF2-D838-42E8-9EBB-1228405DE73BQ33715239-0BBD7EF9-ED3C-4161-A100-A8AAE5880FBCQ33836947-A6002299-C472-4443-ABA5-91686294286CQ34046040-C4553AF2-7D0B-45E8-9946-35BADD4B9DCDQ34496928-A49869AE-BCAD-45B9-8268-BECD5602A4ACQ35840623-787E3FAA-1D27-48D1-AAF2-2040D49ECCA3Q36769219-381783C3-4269-4316-B6F2-C72523758D88Q37070395-89C7A8ED-D02A-41F9-85B3-0DB24E2EB50EQ37781045-E1AD9546-B8FF-4C0F-A560-CC2B6B755D63Q38166972-A4E91ABB-D316-477C-804C-05D4914EDE3FQ38253573-75C6AC7D-63C8-46CB-8BD7-F0189CE3EB22Q38370609-C888B5E6-AE5A-4C36-A52E-7A9083532C58Q40793617-9EE814E9-8EAD-421D-AD55-544A570D3364Q41975639-71C3B9A3-BDE5-4032-8501-05805194D8E2Q48009480-C2661FFF-ACBF-44DA-864E-DA13AFA161C6Q49022359-72DF78CB-FF79-49E8-9E4F-575F4FD06895Q55020340-7C442E4B-3FD9-4F65-9A9D-1876D440A9DE
P2860
PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
PET imaging of the in vivo bra ...... mine-treated patients with AD.
@en
PET imaging of the in vivo bra ...... mine-treated patients with AD.
@nl
type
label
PET imaging of the in vivo bra ...... mine-treated patients with AD.
@en
PET imaging of the in vivo bra ...... mine-treated patients with AD.
@nl
prefLabel
PET imaging of the in vivo bra ...... mine-treated patients with AD.
@en
PET imaging of the in vivo bra ...... mine-treated patients with AD.
@nl
P2093
P50
P1476
PET imaging of the in vivo bra ...... amine-treated patients with AD
@en
P2093
P304
P356
10.1016/J.NEUROBIOLAGING.2007.02.020
P577
2007-03-26T00:00:00Z